Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer

Abstract Immune checkpoint inhibitors (ICI), pembrolizumab and atezolizumab, were recently approved for treatment‐refractory triple‐negative breast cancer (TNBC), where those with Programmed death‐ligand 1 (PD‐L1) positive early‐stage disease had improved responses. ICIs are administered systemicall...

Full description

Bibliographic Details
Main Authors: Hsuan‐Chen Liu, Simone Capuani, Andrew A. Badachhape, Nicola Di Trani, Daniel Davila Gonzalez, Robin S. Vander Pol, Dixita I. Viswanath, Shani Saunders, Nathanael Hernandez, Ketan B. Ghaghada, Shu‐Hsia Chen, Elizabeth Nance, Ananth V. Annapragada, Corrine Ying Xuan Chua, Alessandro Grattoni
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Bioengineering & Translational Medicine
Subjects:
anti PD‐L1
biodistribution
CT
drug delivery
radiotherapy
TNBC
Online Access:https://doi.org/10.1002/btm2.10594

Internet

https://doi.org/10.1002/btm2.10594

Similar Items